Taking the evidence altogether, we consider extended use of endocrine therapy including an aromatase inhibitor as a good treatment strategy for patients with luminal A-like breast cancer, whereas additional targeted therapies may be indicated for patients with luminal B-like tumours. The gene discussed is CYP19A1; the disease is breast carcinoma.